BioCorRx Inc. Now Included in Market Intelligence Provider's List of Covered Stocks

BioCorRx BICX updated market data is now available on Standard & Poor Capital IQ Factual Stock Reports, S&P Capital IQ stated in a news release. S&P Capital IQ started its coverage on the stocks of the Santa Ana, California-based addiction rehabilitation company in April.

According to the stock report, BioCorRx stock closed at $0.16 on Friday. It traded at a price range between $0.03 and $0.31 over the previous 52 weeks. 

The Factual Stock Report also includes a peer comparison of BioCorRx with Nasdaq-listed small-cap Acadia Healthcare Co. and fellow micro-cap AdCare Health Systems Inc. The report also showed company versus market comparisons for the current time period up to April 2014.

Movements on the said comparative charts reveal an uptick in BioCorRx valuation moving forward. 

Copies of the S&P Capital IQ’s Factual Stock Report on BioCorRx will be made available to investors and brokers who use S&P Capital IQ data platforms through their e-brokerage accounts.

S&P Capital IQ disclosed that it receives compensation for initiating coverage and distributing reports on a particular stock.  

Fundamental outlook for the healthcare industry, under which BioCorRx was categorized by S&P Capital IQ, will remain neutral, S&P senior industry analyst Steven Silver said in the Factual Stock Report. Company valuations are expected to be volatile as the number of new patients with access to insurance fluctuates and as the population sees a shift to ambulatory care.

Healthcare policy reforms, service diversification and M&As among hospitals will help keep expenses down for health care providers despite Medicare and Medicaid reimbursement cuts, according to Silver. 

The report also noted that the S&P Health Care Facilities Index was up by 46.1 percent in 2013, outperforming the S&P 1500 Composite Index’s 30.1 percent increase. By contrast, the said index soared by 29.1 percent in 2012, while the S&P 1500 advanced by only 13.7 percent during the same year.  

BioCorRx found success with its cost-effective alcohol treatment program called Start Fresh Program which incorporates a two-step rehabilitation program. The program combines the use of a Naltrexone time-release implant, which slowly releases Naltrexone into the patient’s blood stream over a 12-month period or less, and psyho-social life coaching.

Clinics using the Start Fresh Program have reported an 85 percent success rate with their patients. 

On Friday, BioCorRx announced it would open a new Start Fresh Program clinic in Atlanta, Georgia in June. Operations of the new clinic will be supervised by BioCorRx medical director Dr. George Fallieras, who also serves as the distributor of other Start Fresh Program clinics in the country. The new clinic is seen to benefit residents of the greater Atlanta metropolitan area as well as nearby major cities.

BioCorRx announced its foray into the opioid rehabilitation market in March under its Start Fresh Program, according to an independent report on Gant Daily. The company uses FDA-approved substance Naltrexone in its implants to treat patients’ opioid dependence. Naltrexone is an opoiod receptor antagonist that effectively curbs a patient’s physical drug cravings.

The company trades at an average volume of 250,505. Its market cap is $20.13 million, Yahoo! Finance data showed.